BridgeBio Pharma, Inc. (BBIO) SEC Filings & Earnings Calls

Lack of financial details; agreement may involve pricing commitments that could pressure margins.

“No financial terms disclosed in excerpt.”

Major shareholder exit

“After giving effect to the Offering, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on August 17, 2026.” · word for word

Major shareholder exit

“After giving effect to the Offering, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on August 17, 2026.” · word for word

Secondary offering may dilute market perception but no direct impact on company's cash position.

“The Company will not receive any of the proceeds from the sale of the Shares being offered by the Selling Stockholder.” · word for word

Regulatory approval risk for pipeline products; PDUFA dates in 2026-2027.

“Three NDAs submitted with PDUFA dates; no guarantee of approval.”

High leverage and debt maturity

“As of June 30, 2026, we had outstanding debt of approximately $2.5 billion related to our convertible senior notes” · word for word

Customer concentration

“As of June 30, 2026, five customers each accounted for more than 10% of our consolidated gross accounts receivable balance, at 26.5%, 19.0%, 18.4%, 14.9% and 14.2%.” · word for word

Dependence on single product

“Our business is substantially dependent on the commercial success of Attruby and Beyonttra.” · word for word

Significant operating losses

“For the six months ended June 30, 2026 and 2025, we incurred net losses of $322.4 million and $353.4 million, respectively.” · word for word

Activist exit / reduced conviction

“As of July 9, 2026, the Reporting Persons ceased to be beneficial owners of more than 5% of the shares of Common Stock.” · word for word

Activist exit / reduced conviction

“As of July 9, 2026, the Reporting Persons ceased to be beneficial owners of more than 5% of the shares of Common Stock.” · word for word

Dilution risk from conversion of preferred stock into common stock.

“Preferred Stock is convertible into shares of Common Stock at $137.79 per share” · word for word

High dividend cost (7% cumulative) increases fixed charges.

“dividends that accrue and accumulate daily ... at a rate of 7.00% per annum”

Potential dilution from ATM offering.

“Company may issue up to $500M in common stock.”

Dependence on Attruby for revenue; pipeline execution risk for upcoming NDAs.

“Revenue heavily concentrated in Attruby; pipeline programs (BBP-418, encaleret, infigratinib) still in regulatory stages.”

Drug pricing reform risk (MFN models)

“We currently derive the substantial portion of our revenue from U.S. sales, and any requirement to pay additional rebates in the U.S. to match international reference prices would impact our overall net product revenue.” · word for word

Tariff risk on pharmaceutical products

“The current administration published significant tariffs on certain pharmaceutical products and ingredients, effective in mid-2026.” · word for word

Commercialization risk for Attruby and Beyonttra

“Our business is substantially dependent on the commercial success of Attruby and Beyonttra.” · word for word

Equity dilution from share increase

“Approval of an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.” · word for word

Say-on-pay vote result (75% support) indicates some shareholder concern

“Approximately 75% of the votes cast by our stockholders on the matter were in favor of our 2024 compensation program.” · word for word

Regulatory risk; FDA review outcome uncertain.

“NDA submitted but not yet accepted or approved.”

Clinical trial and regulatory risk for pipeline assets; NDA submissions and approvals not guaranteed.

“Multiple NDA submissions planned for 1H 2026; regulatory outcomes uncertain.”

Commercial execution risk for Attruby; competition from other ATTR-CM therapies.

“Attruby commercial launch ongoing; market share and pricing dynamics.”

Drug pricing reform (MFN) could reduce net product revenue

“In December 2025, CMS announced proposals for new mandatory demonstration payment models... GLOBE for Medicare Part B and GUARD for Medicare Part D. If finalized, these models would impose additional mandatory rebates on manufacturers... if the Medicare prices for such products exceed those paid in economically comparable countries. We currently derive the s” · word for word

Dependence on Attruby and Beyonttra commercial success

“Our business is substantially dependent on the commercial success of Attruby and Beyonttra.” · word for word

Coverage and reimbursement uncertainty

“The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business.” · word for word

Regulatory and commercial risk for infigratinib; NDA submission and approval not guaranteed.

“Phase 3 results positive but regulatory path ahead.”

Potential dilution from convertible notes if converted.

“0.75% Convertible Senior Notes due 2033; conversion could dilute existing shareholders.” · word for word

Increased leverage from debt issuance.

“$575M in convertible senior notes.”

Dependence on Attruby commercial success; limited revenue diversification.

“Revenue entirely from Attruby; no other product revenue mentioned.”

High cash burn rate

“Net cash used in operating activities was $389.5 million for the nine months ended September 30, 2025.” · word for word

Significant debt and royalty obligations

“As of September 30, 2025, we have outstanding debt of $1.9 billion and deferred royalty obligations, net of $844.7 million.” · word for word

Dependence on Attruby/Beyonttra commercial success

“Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our commercialization strategy for acoramidis.” · word for word

Single source manufacturer risk

“We rely and expect to continue to rely on a small number of manufacturers, and in some cases a single source manufacturer, to supply us with our requirements for the active pharmaceutical ingredients and formulated drugs related to the sale of our commercial product.” · word for word

Restructuring execution risk

“We may not realize the anticipated efficiencies and other benefits of our past and any future restructuring initiatives.” · word for word

Clinical trial success reduces pipeline risk but regulatory and commercial risks remain.

“Positive Phase 3 results; further development and approval required.”